Related Experiment Video
Updated: Jun 12, 2026
07:17
Exploring the Application of Surface-enhanced Raman Scattering-based Biosensing of Individual sEVs in Disease Diagnosis and Therapeutics
Published on: March 13, 2026
Early Screening for Cervical Squamous Cell Carcinoma and Precancerous Lesions Based on Surface-Enhanced Raman
Ji Xia1,2, Jianhao Sun1,2, Dan Lu1,2
1Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou University, Yangzhou, People's Republic of China.
International Journal of Nanomedicine
|June 11, 2026
Summary
This study presents a novel microarray chip using surface-enhanced Raman scattering (SERS) for sensitive detection of cervical cancer biomarkers, miRNA103a and miRNA221, in serum. The developed SERS microarray chip shows promise for early cervical cancer screening and distinguishing disease states.
Area of Science:
- Biotechnology
- Nanotechnology
- Molecular Diagnostics
Background:
- MicroRNAs (miRNAs) are crucial in tumor development and metastasis, with serum concentrations indicating cancer progression and diagnostic potential.
- Cervical cancer diagnosis can be improved by detecting specific miRNA biomarkers in serum.
Purpose of the Study:
- To develop a highly sensitive microarray chip utilizing surface-enhanced Raman scattering (SERS) technology.
- To enable simultaneous and repeatable detection of cervical cancer biomarkers, specifically miRNA103a and miRNA221.
Main Methods:
- Constructed a microarray chip with gold-silver nanoboxes (Au-AgNBs) functionalized with capture DNA for miRNA103a and miRNA221.
- Employed SERS technology for signal enhancement and a double-stranded nucleic acid-specific nuclease (DSN nuclease) for signal generation.
- Analyzed serum samples from healthy individuals and patients with varying stages of cervical intraepithelial neoplasia and cervical cancer using the microarray chip and qRT-PCR.
Main Results:
- The SERS microarray chip demonstrated excellent reproducibility and sensitivity, with low detection limits for miRNA-103a (1.0934 × 10⁻¹⁴ M/L) and miRNA-221 (7.5667 × 10⁻¹³ M/L).
- Results from the microarray chip showed less than 10% relative error compared to qRT-PCR, with statistically significant findings (P < 0.05).
Conclusions:
- Microarray chips offer a reliable method for early cervical cancer screening.
- The developed SERS microarray chip is efficient for multi-sample experiments and effectively differentiates between healthy individuals and various stages of cervical disease.
